Correlation Between Cytek Biosciences and BioCryst Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Cytek Biosciences and BioCryst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cytek Biosciences and BioCryst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cytek Biosciences and BioCryst Pharmaceuticals, you can compare the effects of market volatilities on Cytek Biosciences and BioCryst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cytek Biosciences with a short position of BioCryst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cytek Biosciences and BioCryst Pharmaceuticals.

Diversification Opportunities for Cytek Biosciences and BioCryst Pharmaceuticals

-0.52

Correlation Coefficient

Cytek Biosciences  BioCryst Pharmaceuticals

Excellent diversification

The 3 months correlation between Cytek and BioCryst is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Cytek Biosciences and BioCryst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioCryst Pharmaceuticals and Cytek Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cytek Biosciences are associated (or correlated) with BioCryst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioCryst Pharmaceuticals has no effect on the direction of Cytek Biosciences i.e., Cytek Biosciences and BioCryst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Cytek Biosciences and BioCryst Pharmaceuticals

Given the investment horizon of 90 days Cytek Biosciences is expected to generate 1.45 times less return on investment than BioCryst Pharmaceuticals. In addition to that, Cytek Biosciences is 1.44 times more volatile than BioCryst Pharmaceuticals. It trades about 0.01 of its total potential returns per unit of risk. BioCryst Pharmaceuticals is currently generating about 0.03 per unit of volatility. If you would invest  832.00  in BioCryst Pharmaceuticals on April 28, 2025 and sell it today you would earn a total of  23.00  from holding BioCryst Pharmaceuticals or generate 2.76% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Cytek Biosciences  vs.  BioCryst Pharmaceuticals

Cytek Biosciences

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Cytek Biosciences are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong forward-looking signals, Cytek Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

BioCryst Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in BioCryst Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, BioCryst Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Pair Trading with Cytek Biosciences and BioCryst Pharmaceuticals

The main advantage of trading using opposite Cytek Biosciences and BioCryst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cytek Biosciences position performs unexpectedly, BioCryst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will offset losses from the drop in BioCryst Pharmaceuticals' long position.

The idea behind Cytek Biosciences and BioCryst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.